How Are Adverse Events From Unapproved Regenerative Products Reported?
Published November 16, 2026
Protocol: 9 steps in this guide
Get medical care first, then report. In the United States, patients, families and health professionals can report a suspected reaction to FDA’s MedWatch program, online or on a paper form, even if no one is sure the product caused it. FDA’s patient and consumer information on regenerative medicine therapies states: “If you were hurt or had a bad side effect following treatment with a regenerative medicine product, or a similar product, we also encourage you to report it to the FDA’s MedWatch Adverse Event Reporting program.” A report is more useful when it names the exact product, where and when it was given, and what happened.
Care comes before paperwork
If you have symptoms that could be serious, such as a high fever, chills, trouble breathing, severe pain, confusion or fainting, call 911 or go to an emergency department. Reporting can wait; treatment cannot. Tell the treating clinicians exactly what product you received and when, because that can affect how they test and treat you.
What counts as a serious adverse event
FDA defines an adverse event as “any undesirable experience associated with the use of a medical product in a patient.” Its page What is a Serious Adverse Event? says an event is serious and should be reported when the outcome is:
- death;
- a life-threatening event;
- hospitalization, initial or prolonged;
- disability or permanent damage;
- a congenital anomaly or birth defect;
- an intervention required to prevent permanent impairment or damage (devices);
- another serious, important medical event.
For regenerative products, FDA’s patient information lists safety concerns including blindness, tumor formation, neurological events, “Bacterial infections including life-threatening blood infections,” reactions at the site of collection and administration, and unwanted inflammatory or immune responses.
How to report to MedWatch
FDA’s MedWatch program is its medical product safety reporting program “for health professionals, patients and consumers,” and it covers biologics, including “human cells and tissue transplants.” FDA’s page on reporting serious problems to FDA lists the options:
| Route | Who it is for |
|---|---|
| Online Reporting Form | Health professionals, patients and consumers |
| Form FDA 3500 | Health professionals, consumers and patients |
| Form FDA 3500B | Patients and consumers; a consumer-friendly version |
| Phone, 1-888-INFO-FDA (1-888-463-6332), then press 2 | Anyone with questions or needing reporting instructions |
FDA encourages you to take the form to your doctor, explaining: “Your health care provider can provide clinical information based on your medical record that can help FDA evaluate your report.” It also notes that your provider “is NOT required to report to the FDA,” and that you can complete the online form yourself. For questions about a specific regenerative product, FDA’s patient information also gives the email address ocod@fda.hhs.gov.
Product details to keep
Keep anything that identifies exactly what you received: the product name, the manufacturer or supplier, the lot or batch number, the label or vial if you have it, receipts and the clinic’s paperwork. Lot numbers matter. In an August 27, 2026 notice, FDA reminded compounders not to use dietary supplement grade glutathione for injectables after reports of “at least 30 patients who experienced adverse events” following IV glutathione. The compounded products came from different pharmacies, but the glutathione had been obtained from one supplier and one lot. Reports like these can reveal a pattern that no single report shows. Glutathione is not a regenerative product; the example shows how product details in reports help trace a problem.
Timeline, medicines and records
Write down the dates of treatment, when symptoms started and how they changed, what medicines and supplements you take, and any other procedures you had around the same time. Ask for copies of clinic notes, test results and discharge papers.
Reader’s reporting worksheet
This worksheet is ours, to help you gather details before you report:
| Item | Your entry |
|---|---|
| Product name, as given by the clinic | |
| Manufacturer or supplier | |
| Lot or batch number | |
| Date and place of treatment | |
| Dose and route, such as joint injection or IV | |
| Symptoms and when each started | |
| Medical care received and outcome | |
| Clinician's assessment, if any | |
| Other medicines, supplements and procedures | |
| Documents you have |
A report does not prove causation
You do not need proof that the product caused the problem. FDA’s definition refers to an experience “associated with” a product, and its serious-event page asks people to report deaths and other outcomes when they “suspect” a link. A single report shows that something happened after a product was used; FDA reviews reports alongside other information. FDA states that it relies on voluntary reporting, adding: “Your report may be the critical action that prompts a modification in use or design of the product, improves its safety profile and leads to increased patient safety.” Why one report is not proof is explained in the difference between a placebo-controlled trial and an observational study.
Other people to tell
Tell your own doctor, who can document the event in your medical record. If the treatment was part of a research study, contact the study team and the contacts listed on your consent form, as described in what should be included in informed consent for an experimental biologic injection; in a study under an Investigational New Drug application, investigators have their own reporting duties, covered in how researchers monitor long-term safety after cell therapy. FDA’s patient information adds: “Please know that if you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.”
Follow-up and privacy
Keep a copy of what you submit and the date. If you have privacy questions, FDA’s reporting page links to a resource titled “HIPAA Compliance for Reporters to FDA MedWatch.” Before receiving any further treatment, check the product’s status using how you can tell whether a regenerative medicine product is FDA-approved.
After urgent care comes first, an adverse event from an unapproved regenerative product can be reported to FDA’s MedWatch program online, on Form 3500 or 3500B, or with help by phone, and a report with the exact product, lot, dates and symptoms is useful even when no one can yet say the product caused the harm.
Cells linked to this one
This guide leads on to
- I8 What Is the Difference Between a Placebo-Controlled Trial and an Observational Study?
- I4 What Should Be Included in Informed Consent for an Experimental Biologic Injection?
- I6 How Do Researchers Monitor Long-Term Safety After Cell Therapy?
- I1 How Can You Tell Whether a Regenerative Medicine Product Is FDA-Approved?
Guides that lead here
- E10 What Are the Risks of Immune Reactions to Donor-Derived Cell Products?
- F11 How Does the FDA Regulate Stem Cell Products Promoted for Joint Pain?
- B7 How Long Does Soreness Last After a PRP Injection?
- E8 What Are Exosomes, and How Do They Differ From Living Cells?
- G6 What Clinical Evidence Supports IV Glutathione for Wellness?
- D6 What Are the Potential Risks of A2M Joint Injections?
Add a remark